COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients (ADENOIBD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03773952
Recruitment Status : Recruiting
First Posted : December 12, 2018
Last Update Posted : December 12, 2018
Information provided by (Responsible Party):
Palobiofarma SL

Brief Summary:
This is a Phase IIa (proof of concept), randomized, double blind, placebo-controlled, multicentre clinical trial to evaluate the safety and efficacy of daily PBF-677 oral treatment during 28 days in Ulcerative colitis (UC) patients who are not receiving immunosuppressants and present mild-to-moderate activity of the disease. Enrolled patients would receive standard high doses of 5-ASA (4g), according to current clinical guidelines, and are randomized to receive also PBF-677 or placebo.

Condition or disease Intervention/treatment Phase
Ulcerative Colitis Drug: PBF-677 Drug: Placebo oral capsule Phase 2

Detailed Description:

This Proof-of-concept clinical trial is carefully designed to establish the safety profile of PBF-677 over 28 days in mild to moderate ulcerative colitis population and explore the relationship between the 200 mg PBF-677 dose and induction of remission, according to clinical parameters (Partial Mayo Score) and a faecal surrogate biomarker of mucosal inflammation (Calprotectin). The trial also will explore the PBF-677 pharmacokinetics (PK) profile during 28 days of administration.

This small-scale study has been designed to detect a signal that PBF-677 is safe and active on decreasing levels of faecal calprotectin, as well as preliminary evidence of ameliorate the Partial Mayo Clinical Score in colitis patients who are in flare of the disease.

The Population Under Study will be: Around 30 subjects. Adults (18-75 years old) non-immunosuppressed patients with mild to moderate active ulcerative colitis disease.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: randomized, double blind, placebo controlled, multicenter clinical trial
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase IIa (Proof of Concept), Randomized, Double Blind, Placebo Controlled, Multicenter Clinical Trial to Evaluate the Safety and Efficacy of Oral Treatment With PBF-677 in Patients With Mild to Moderate Ulcerative Colitis
Actual Study Start Date : July 1, 2018
Estimated Primary Completion Date : June 30, 2020
Estimated Study Completion Date : December 30, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Oral 5-ASA + PBF-677 200 mg
Oral Mesalazine (5-ASA) (4g) + PBF-677 (200mg)
Drug: PBF-677
oral small molecule, antagonist of Adenosine A3 receptor (AA3R)

Placebo Comparator: Oral 5-ASA + Placebo oral Capsules
Oral Mesalazine (5-ASA) (4g) + Placebo oral capsules
Drug: Placebo oral capsule
Oral capsules

Primary Outcome Measures :
  1. Number of subjects with treatment-related adverse events as assessed by CTCAE v4.03" [ Time Frame: 28 Days ]
    Adverse events will be assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. If

Secondary Outcome Measures :
  1. Effect of PBF-677 on Faecal calprotectin levels [ Time Frame: 28 Days ]
    Calprotectin levels in stools is a validated biomarker of the severity of the disease. A decrease in the calprotectin levels under 50 mg/Kg is associated with the remission of the disease flare.

  2. Effect of PBF-677 on Ulcerative Colitis activity [ Time Frame: 28 Days ]

    The assessment Will be based on the Partial Mayo Scoring Index that sum and score the following ítems:

    1. Stool Frequency (based on the past 3 days)
    2. Rectal Bleeding (based on the past 3 days)
    3. Physician's Global Assessment

    The scoring range is as follow:

    Remission = 0-1 Mild Disease = 2-4 Moderate Disease = 5-6 Severe Disease =7-9

  3. Pharmacokinetic PBF-677 peak concentration in plasma [ Time Frame: Day 1 and Day 14 ]
    The parameter will be calculated from plasma samples collected at days 1 and 14 after drug administration. It will consist in the maximum plasma concentration (ng/mL) of PBF-677 observed after administration

  4. Pharmacokinetic Time to PBF-677 peak concentration in plasma "Tmax" [ Time Frame: Day 1 and Day 14 ]
    The parameter will be calculated from plasma samples collected at days 1 and 14 after drug administration.It will consist in the time (in minutes) to reach the maximum "PBF-677" concentration in plasma samples of patients after oral administration of PBF-677.

  5. Pharmacokinetic Area under curve (AUC) of PBF-677 in plasma [ Time Frame: Day 1 and Day 14 ]
    The parameter will be calculated from plasma samples collected at days 1 and 14 after drug administration. It will consist in the area under the concentration-time curve from zero up to ∞ with extrapolation of the terminal phase. "AUC(0-inf)" will be given in Amount·time/ volume units

  6. Pharmacokinetic Ctrough plasma concentration of PBF-677 [ Time Frame: Day 1 and Day 14 ]
    Trough plasma concentration (measured concentration at the end of a dosing interval at steady state [taken directly before next administration])

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Able and willing to provide written informed consent
  • Male or Female, 18 to 75 years of age, inclusive
  • Patient with previous diagnosis of ulcerative colitis: ulcerative proctitis, left-side ulcerative colitis or extensive/pancolitis (E1, E2 and E3 of Montreal Classification, respectively) established at least 3 months prior to screening and determined by ordinary clinical, endoscopic, and histological procedures.
  • Patient who has stable oral 5-ASA dose < 4 gr/day treatment, within 1 month prior to screening.
  • Mild-to-moderate activity of the disease determined clinically during the screening period by Partial Mayo Clinical Score of ≤ 6, with rectal bleeding score ≤ 2 and/or a bowel frequency score ≤ 2.
  • Patient in flare of the disease.
  • Patient with faecal calprotectin levels > 50 mg/Kg
  • Availability for the entire study period, absence of intellectual problems likely to limit the validity of consent to participate in the study or the compliance with protocol requirements; willingness to adhere to the protocol requirements, ability to cooperate adequately, to understand and follow the instructions of the physician or designee.
  • Women who are not postmenopausal (at least 12 months) or surgically sterile must have a negative pregnancy test at screening and at the end of study and either abstain from sexual intercourse or use a highly effective method of birth control for the duration of the study and after 12 weeks after the last dose of study drug.
  • For men: agreement to remain abstinent or use contraceptive measures and agreement to refrain from donating sperm for the duration of the study and after 12 weeks from the last dose of study drug.

Exclusion Criteria:

  • Patient who has treatment, within 3 months prior to screening, with immunomodulators including corticosteroids, azathioprine, mercaptopurine, biologics, tacrolimus, cyclosporine, for disease control.
  • Patient who has stable oral 5-ASA dose ≥ 4 gr/day treatment, within 1 month prior to screening.
  • Patient with C-reactive Protein levels (CRP) ≥ 10 mg/L
  • Patient who has anti-diarrheal treatment, within 3 months prior to screening.
  • Use of prescription medications started or with a dose adjustment within 4 weeks prior to study enrolment, or OTC medications or supplements started or with a dose adjustment within 2 weeks prior study enrolment.
  • Use of products, food supplements or medical devices, whose composition includes probiotics in the 3 months prior to the selection.
  • Patient who has fulminant or severe colitis, toxic megacolon, primary sclerosing cholangitis, Crohn's disease, history of colitis associated colonic dysplasia or active peptic ulcer disease.
  • Patient who has prior extensive colonic resection, subtotal or total colectomy or planned surgery for UC
  • Patient who has past or present fistula or abdominal abscess
  • Patient who has clinically significant diseases and/or infections captured in the medical history or evidence of clinically significant findings on physical examination and/or clinically significant ordinary laboratory evaluations (haematology, biochemistry, and urinalysis) or ECG.
  • Patient who has evidence of significant liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects
  • Patient who is currently participating in another clinical trial of an investigational drug or medical device within 90 days prior to screening.
  • Patient who is pregnant or lactating
  • Inability to comply with study protocol, in opinion of the investigator
  • History of alcohol, drug or chemical abuse within 6 months prior to screening
  • History of cancer except local basal or squamous cell carcinoma of the skin that has been excised and is considered cured.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03773952

Layout table for location contacts
Contact: Nahomi Castro Palomino, Ph.D +34 936500035
Contact: Tamara Cordero

Layout table for location information
Unidad de Enfermedad Inflamatoria Intestinal / IBD Unit. Servicio de Gastroenterología y Hepatología / Gastroenterology and Hepatology Dpt. Study Medical Coordinator Hospital Universitario Puerta de Hierro Recruiting
Madrid, Spain
Contact: Yago González Lama, MD, PhD         
Sponsors and Collaborators
Palobiofarma SL
Layout table for additonal information
Responsible Party: Palobiofarma SL Identifier: NCT03773952    
Other Study ID Numbers: PBF-677-3
First Posted: December 12, 2018    Key Record Dates
Last Update Posted: December 12, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Colitis, Ulcerative
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Pathologic Processes
Inflammatory Bowel Diseases